The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals’ Daybue Stix (trofinetide).
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Travel + Leisure on MSN
This Easy Hike in Acadia National Park Is One of Its Most Scenic—With Peaceful Forest, a Mirror-like Lake, and Mountain Backdrops
The Jordan Pond Path in Acadia National Park is a scenic 3.3-mile loop with calm shoreline views, views of the famous Bubbles ...
Visitors to Acadia National Park in Maine will no longer be able to enter for free on Martin Luther King Jr. Day or ...
Acadia Pharmaceuticals Inc. is rated a Buy for its steady NUPLAZID/DAYBUE franchises & pipeline-driven upside potential. Read ...
ACADIA Pharmaceuticals generates revenue primarily through the commercialization of NUPLAZID for Parkinson's disease ...
Friends of Acadia estimates the park lost about $1.75M in entry revenue in October 2025 alone, not to mention the first two ...
TipRanks on MSN
Neuren Pharmaceuticals’ partner Acadia gains FDA approval for new Rett syndrome treatment
Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has provided an update. Neuren Pharmaceuticals announced that its partner, Acadia Pharmaceuticals, ...
Acadia Healthcare stock fell after revising its 2025 outlook due to higher litigation costs stemming from patient-related ...
We bought a 2024 GMC Acadia Elevation AWD for $49,190—anonymously from an area dealer, as we do with every vehicle we ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback